Thienopyridines and statins: Assessing a potential drug-drug interaction

Current Pharmaceutical Design

Volumn 12, Issue 10, 2006, Pages 1271-1280

  Neubauer, H ^a   Mügge, Andreas ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Aggregometer; Clopidogrel; Cytochrome P450; Flow cytometry; Interaction; Statin; Thienopyridine

Indexed keywords

3 METHYLCHOLANTHRENE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA NAPHTHOFLAVONE; CALCIUM ANTAGONIST; CERIVASTATIN; CLOPIDOGREL; CYTOCHROME P450 1A1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EPTIFIBATIDE; ERYTHROMYCIN; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; PURINE P2Y12 RECEPTOR; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; THIENOPYRIDINE DERIVATIVE; THROMBOCYTE RECEPTOR; TICLOPIDINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ANTITHROMBOCYTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; HYPOCHOLESTEROLEMIC AGENT; PYRIDINE DERIVATIVE; THIENOPYRIDINE;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; BLOOD TOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY STENT; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STABILITY; DYSLIPIDEMIA; FLOW CYTOMETRY; HUMAN; ISCHEMIC HEART DISEASE; LIVER METABOLISM; MYOPATHY; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; RHABDOMYOLYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; ANIMAL; BIOTRANSFORMATION; DRUG INTERACTION; METABOLISM;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; PYRIDINES;

EID: 33744975050     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776361354     Document Type: Review

References (63)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-7.
3. Nawarskas JJ. Clopidogrel-statin interaction. Cardiol Rev 2004; 12: 236-9.
4. Ford I, Williams D. Does the use of statins compromise the effectiveness of platelet inhibition by clopidogrel? Platelets 2004; 15: 201-5.
5. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of anti-platelet agents. The task force an the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25: 166-81.
6. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
7. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107: 1591-8.
8. Lubbe DF, Berger PB. The thienopyridines. J Interv Cardiol 2002; 15: 85-93.
9. Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. In vitro inhibition of the cytochrome P450 (CYP450) system by the anti-platelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 2000; 49: 343-51.
10. Herbert JM, Savi P, Maffrand JP. Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist. Eur Heart J 1999; 1(Suppl A): A31-A40.
11. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, et al. Importance of hepatic metabolism for the anti-aggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-32.
12. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, et al. The antiaggregrating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994; 72: 313-7.
13. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 53-9.
14. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-71.
15. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
16. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-6.
17. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002: 11: 1288-95.
18. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimen: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999; 25: 15-9.
19. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, Von Beckerath N, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311-6.
20. Wiviott SD, Antman EM. Clopidogrel resistance: a now chapter in a fast-moving story. Circulation 2004; 109: 3064-7.
21. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without loading dose regimen in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102: 624-9.
22. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001; 345: 494-502.
23. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE-study. Lancet 2001; 358: 527-533.
24. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
25. Chen ZM, Jiang LX, Chen YP, Xie JY, Pan HC, Peto R, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-21.
26. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. CLARITY-TIMI 28 Investigators. N Engl J Med 2005; 352: 1179-89.
27. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double- blind, placebo-controlled trial. Lancet 2004; 364: 331-7.
28. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail 2005; 7: 1070-5.
29. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57: 640-51.
30. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34.
31. Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002; 42: 835-45.
32. Bellosta S, Paoletti P, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109 (Suppl 1): 50-7.
33. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation 2004; 110: 886-92.
34. Bottorff MB. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors. Arch Intern Med 2000; 160: 2273-80.
35. Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc 2000; 40: 637-44.
36. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-70.
37. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study. Eur Heart J 2003; 24: 1744-9.
38. Muller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003; 108: 2195-7.
39. Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schomig A, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004; 25: 1898-902.
40. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004; 109: 1335-8.
41. Serebruany VL, Malinin AI, Callahan KP, Gurbel PA, Steinhubl SR. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis 2001; 159: 239-41.
42. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004; 164: 2051-7.
43. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-4.
44. Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92: 285-8.
45. Montague T, Cox J, Kramer S, Nemis-White J, Cochrane B, Wheatley M, et al. Improving cardiovascular outcomes in Nova Scotia (ICONS): a successful public- private partnership in primary healthcare. Hosp Q 2003; 6: 32-8.
46. Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004; 140: 857-66.
47. Kastrati A, Schomig A, Schomig E. Are we making efficient use of clopidogrel? Eur Heart J 2004; 25: 454-6.
48. Kastrati A, Von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004; 110: 1916-9.
49. Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999; 25(Suppl 2): 25-8.
50. McEwen J, Strauch G, Perles P, Pritchard G, Moreland TE, Necciari J, et al. Clopidogrel bioavailability: absence of influence of food or antacids. Semin Thromb Hemost 1999; 25(Suppl 2): 47-50.
51. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-95.
52. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992; 80: 2787-96.
53. Denninger MH, Necciari J, Serre-Lacroix E, Sissmann J. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. Semin Thromb Hemost 1999; 25(Suppl 2): 41-5.
54. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-8.
55. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistence, and the effect of pretreatment platelet reactivity. Circulation 2003; 107; 2908-2913.
56. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004; 93: 456-8.
57. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
58. Lepantalo A, Virtanen KS, Heikkila J, Wartiovaara U, Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 2004; 25(6): 476-83.
59. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-51.
60. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg J, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232-8.
61. Buemi M, Aloisi C, Fulvio F, Caccamo C, Cavallaro E, Crasci E, Criseo M, Corica F, Frisina N. Cardiorenal consequences of atherosclerosis and statins therapy: from the past to the future. Curr Pharm Des 2005; 11(30): 3973-84.
62. Koida M, Fukuyama R, Nakamuta H. Osteoporosis requires bone-specific statins. Curr Pharm Des 2004; 10(21): 2605-13.
63. Walter DH. Insights into early and rapid effects of statin therapy after coronary interventions. Curr Pharm Des 2004; 10(4): 369-73.